BioNTech Invests $25M Upfront to Enhance ADC Partnership with China’s MediLink

CAR-T Digest - August 2020

28 May 2024: BioNTech Invests $25M Upfront to Enhance ADC Partnership with China’s MediLink

BioNTech is paying $25 million upfront to collaborate with MediLink Therapeutics on using its TMALIN ADC platform for undisclosed solid-tumor targets
Earlier in October 2023 BioNTech paid $70 million upfront for a HER3-directed ADC, with potential payouts up to $1 billion
The HER3-directed ADC is being tested in non-small cell lung cancer and breast cancer, showing promising preclinical results
BioNTech has also partnered with China-based Duality Biologics, paying $170 million upfront in April 2023 for rights to two ADCs
MediLink has attracted other major partners, including Roche, which signed a deal worth over $1 billion for MediLink’s c-Met targeting ADC candidate for solid tumors.